06 September 2018
A report published by visiongain forecasts the worldwide medical biobanking industry will achieve revenues of $27.54 billion in 2020. That sales prediction and others appear in Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells. In April 2016 that updated study appeared.
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand industries and markets in healthcare and other fields, especially their commercial prospects.
The biobanking market will expand its overall revenues at a CAGR of 9.5% between 2015 and 2026, the new study predicts. Biobanking holds high commercial potential, serving important needs in pharmaceutical research and development, as well as basic medical research. In 2015 biobanks for research purposes formed the most lucrative part of that industry, accounting for 77.1% of the overall world market. The study shows that segment will show strong revenue expansion from 2015 to 2026.
That report’s author said: “With the ever increasing need for novel therapies and the shift towards precision medicine, high quality biobanking samples are in great demand. To meet demand, those in the biobanking industry will have to move towards standardisation and harmonisation, as well as planning ahead towards long-term financial sustainability. Another important factor will be increasing public awareness to facilitate participation, as sample donation is critical to the success of biobanking.”
Visiongain’s updated investigation shows revenue forecasts to 2026 at world market, submarket and national level. It forecasts biobanking for research and for therapeutic uses in human medicine. It also forecasts the numbers of samples stored for those two uses.
That report predicts revenues to 2026 for the following subsectors of biobanking for research:
• Human tissues (further divided to commercial and public sectors)
• Stem cells
• Other biological samples (e.g. DNA, RNA, body fluids).
The study also predicts revenues to 2026 for the following segments of biobanking for therapeutic uses:
• Umbilical cord stem cell banking
• Adult stem cell banking.
Furthermore the work analyses 12 leading national markets for biobanking, providing revenue forecasts to 2026 for each:
• The US
• Germany, France, the UK, Italy, Spain and the Netherlands
• Brazil, Russia, India and China.
Visiongain’s survey examines leading biorepositories and related companies. That work also discusses systems, software, consumables and services used by biobanks. That 248 page report gives 72 tables, 74 charts and two interviews with authorities in that field.
Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells adds to visiongain’s analytical portfolio on industries and markets in healthcare. Those reports cover pharmaceuticals, medical devices, diagnostics and outsourced services.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.